Citations

Clear

65 citation(s) found for "Spinelli, A".

A Prognostic Index for Advanced Biliary Tract Cancer Treated With Cisplatin, Gemcitabine and Durvalumab: The MAGIC ‐D Index
Persano, Mara , Rimini, Margherita , Salani, Francesca , Prinzi, Federica Lo , Saborowski, Anna , Antonuzzo, Lorenzo , Passeri, Laura , Satake, Tomoyuki, Peeters, Frederik , Pressiani, Tiziana , Corallo, Salvatore , Finkelmeier, Fabian , Pircher, Chiara , Braconi, Chiara , Qaisar, Aitzaz, Pirrone, Chiara, Castet, Florian , Parisi, Alessandro , Scartozzi, Mario, Perkhofer, Lukas , Adeva, Jorge , Spinelli, Gian Paolo , Rodriquenz, Maria Grazia , Leo, Silvana, Alvim, Cecilia Melo, Roque, Ricardo , Rosa, Antonio De, Lanzetta, Irene, Balsano, Rita , Lavacchi, Daniele, Ikeda, Masafumi, Dekervel, Jeroen , Niger, Monica, Tesini, Giulia , Boccaccino, Alessandra , Himmelsbach, Vera, Vogel, Arndt, Rimassa, Lorenza , Casadei‐Gardini, Andrea, Vogel, Arndt , Casadei‐Gardini, Andrea , Kim, Jin Won , Abidoye, Oluseyi , Corallo, Salvatore , Rapposelli, Ilario Giovanni , Finkelmeier, Fabian , Pircher, Chiara , Pirrone, Chiara , Castet, Florian , Yoo, Changhoon , Oneda, Ester , Couto, Nuno , Adeva, Jorge , Tesini, Giulia , Djaballah, Selma Ahcene , Rimassa, Lorenza , Casadei-Gardini, Andrea , Antonuzzo, Lorenzo , Parisi, Alessandro , Casadei-Gardini, Andrea , Saborowski, Anna , Pressiani, Tiziana , Roque, Ricardo , Salani, Francesca , De Rosa, Antonio , Dekervel, Jeroen , Vogel, Arndt , Rimini, Margherita , Nichetti, Federico , Vivaldi, Caterina , Lucchetti, Jessica , Kim, Jin Won , Tamberi, Stefano , Giordano, Guido , Chon, Hong Jae , Tamburini, Emiliano , Diana, Anna , Scartozzi, Mario , Prager, Gerald W. , Avallone, Antonio , Schirripa, Marta , Kim, Il Hwan , Verrico, Monica , Chan, Stephen L. , Personeni, Nicola , Garajova, Ingrid , Farinea, Giovanni , Fornaro, Lorenzo , Camera, Silvia , Ikeda, Masafumi , Niger, Monica , Tonini, Giuseppe , Kang, Minsu , Bekaii‐Saab, Tanios , Esposito, Luca , Ferrara, Michele , Landriscina, Matteo , Masi, Gianluca , Lonardi, Sara

Mayo Clinic

Liver International | June 17, 2025 | Volume: 45 | Issue: 7 | Pages: No page available

10.1111/liv.70181 | PMID 40525496 Get It

ABSTRACT Background Over the years, prognostic indexes have been developed to help clinicians stratify patients with biliary tract cancers (BTC) into risk groups. This study aims to identify a new prognostic index for patients with BTC treated with cisplatin, gemcitabine and durvalumab (CGD) in the first‐line setting. Patients and Methods The study population consisted of patients with BTC from 11 Eastern and Western Countries. Using multivariate analysis for overall survival (OS), we identified 5 baseline statistically significant variables: stage, carcinoembryonic antigen (CEA) levels, albumin levels, gamma glutamyl transferase (GGT) levels, neutrophil‐to‐lymphocyte ratio (NLR). Metastatic disease is a prognostic factor with a superior weight considering the HR of 3.62, while all the others can be considered prognostic factors with equivalent weight as the HRs are quite similar (HRs between 1.55 and 1.92). Based on these reasons, we developed a prognostic model called the MAGIC‐D index by assigning a score of 2 for metastatic disease, and a score of 1 for CEA increased levels, albumin decreased levels, GGT increased levels, NLR ≥ 3. Patients were stratified into three risk groups as follows: low‐risk group (Score from 0 to 2), intermediate‐risk group (Score from 3 to 4) and high‐risk group (Score from 5 to 6). At the first data cutoff (April 2024), these data were available for 319 patients that composed the training cohort used for the analysis. At the second data cutoff (May 2025), 79 patients were further enrolled and composed the validation cohort. Results Median progression‐free survival was 11.7 months in low‐risk group (20.7%), 8.7 months in intermediate‐risk group (46.4%) and 5.4 months in high‐risk group (32.9%) [low‐risk hazard ratio (HR): 0.27, intermediate‐risk HR: 0.55, high‐risk HR: 1, p < 0.0001]. Median OS was 18.4 months in low‐risk group,15.9 months in intermediate‐risk group and 7.8 months in high‐risk group (low‐risk HR: 0.17, intermediate‐risk HR: 0.43, high‐risk HR: 1, p < 0.0001). There was no difference in overall response rate (low‐risk: 31.8%, intermediate‐risk: 36.5% and high‐risk: 25.7%; p = 0.0718), while disease control rate was significantly different across the three risk groups (low‐risk: 83.3%, intermediate‐risk: 70.9% and high‐risk: 60.9%; p < 0.0001) as well as the rate of patients receiving a second‐line therapy (low‐risk: 54.5%, intermediate‐risk: 48.6% and high‐risk: 25.7%; p = 0.0061). Finally, the prognostic role in terms of OS and PFS of the MAGIC‐D index was confirmed in a validation cohort of 79 patients. Conclusion The MAGIC‐D index is an easy‐to‐use tool able to stratify patients with BTC with different prognoses undergoing first‐line therapy with CGD.
Impact of elective surgery on tumor necrosis factor‐α, interleukin‐6 and quality of life in uncomplicated diverticular disease
Sassun, Richard , Roufael, Francesca, Crippa, Jacopo , Achilli, Pietro , Dinuzzi, Vincenza Paola , Maggioni, Dario, Costanzi, Andrea , Siracusa, Claudia , Leoni, Valerio , Mari, Giulio , Achilli, P , Larson, David Wesley, Crippa, J , Sassun, Richard , Magistro, Carmelo , Bertoglio, Camillo Leonardo , Montroni, Isacco , Spinelli, Antonino , Dominici, Roberto , Larson, David W.

Mayo Clinic

Colorectal Disease | June 10, 2025 | Volume: 27 | Issue: 6 | Pages: No page available

10.1111/codi.70132 | PMID 40491034 Get It

Abstract Aim Growing evidence suggests that immune/inflammatory pathways play a crucial role in the persistence of symptoms in diverticular disease (DD). We hypothesize that chronic diverticulitis triggers a self‐sustained inflammatory status which can be detected by measuring the levels of tumor necrosis factor‐α (TNF‐α) and interleukin‐6 (IL‐6). The aim of this study was to investigate the systemic levels of TNF‐α and IL‐6 before and after elective surgery in patients with DD, and their relationship with the gastrointestinal quality of life index (GIQLI) score. Method This prospective multicentric study enrolled patients from the Diverticular Disease Registry (DDR‐Trial, NCT04907383). All adult patients diagnosed with symptomatic uncomplicated diverticular disease (SUDD), uncomplicated recurrent diverticulitis (URD) and smouldering diverticulitis (SmD) between 1st December 2022 and 31st December 2023 were included in this study. Exclusion criteria were as follows: no surgery, a concurrent chronic immunomodulated systemic disease, a SARS‐CoV‐2‐positive test in the previous 12 months, a history of cancer in the previous 5 years, patients treated with immunomodulators, an American Society of Anesthesiologists category of class IV, and complicated acute diverticulitis. Results Seventy‐two patients were included: 52 (72%) with URD, 11 (15%) with SUDD, and nine (13%) with SmD. The median postsurgery – presurgery (Δ)IL‐6 and ΔTNF‐α levels were −16.8 and −17.3 pg/mL, respectively ( p < 0.001 for both; Wilcoxon test). Spearman correlation revealed a significant, negative association between the ΔGIQLI and the ΔIL‐6, as well as the ΔTNF‐α ( p < 0.001 for both). Greater reduction in the levels of IL‐6 and TNF‐α following surgery are associated with higher GIQLI scores postoperatively. Conclusion Patients with chronic diverticulitis may experience persistent systemic inflammation driven by a colonic trigger. Surgical removal of this trigger appears to enhance GIQLI outcomes reducing IL‐6 and TNF‐α across surgery.
Factors associated with reaching maintenance therapy in patients with advanced biliary tract cancer treated with durvalumab: Real‐world results from a multicenter and multinational study
Rimini, Margherita , Fornaro, Lorenzo , Prinzi, Federica Lo , Saborowski, Anna , Antonuzzo, Lorenzo , Rossari, Federico , Satake, Tomoyuki, Peeters, Frederik , Vivaldi, Caterina , Pressiani, Tiziana , Finkelmeier, Fabian , Pircher, Chiara , Chon, Hong Jae , Braconi, Chiara , Qaisar, Aitzaz, Pirrone, Chiara, Castet, Florian , Parisi, Alessandro , Scartozzi, Mario, Perkhofer, Lukas , Adeva, Jorge , Spinelli, Gian Paolo , Rodriquenz, Maria Grazia , Leo, Silvana, Alvim, Cecilia Melo, Roque, Ricardo , Salani, Francesca , Rosa, Antonio De, Lavacchi, Daniele, Dekervel, Jeroen , Balsano, Rita , Corallo, Salvatore , Esposito, Luca, Boccaccino, Alessandra , Vitiello, Francesco , Himmelsbach, Vera, Tesini, Giulia , Vogel, Arndt, Rimassa, Lorenza , Casadei‐Gardini, Andrea , Vogel, Arndt , Rossari, Federico , Vivaldi, Caterina , Abidoye, Oluseyi , Prager, Gerald W , Niger, Monica , Casadei-Gardini, Andrea , Antonuzzo, Lorenzo , Parisi, Alessandro , Corallo, Salvatore , Finkelmeier, Fabian , Castet, Florian , Adeva, Jorge , Tesini, Giulia , Rimassa, Lorenza , Casadei-Gardini, Andrea , Saborowski, Anna , Pressiani, Tiziana , Jae Chon, Hong , Roque, Ricardo , Salani, Francesca , De Rosa, Antonio , Dekervel, Jeroen , Vogel, Arndt , Rimini, Margherita , Fornaro, Lorenzo , Lucchetti, Jessica , Kim, Jin Won , Rapposelli, Ilario Giovanni , Tamberi, Stefano , Giordano, Guido , Tamburini, Emiliano , Yoo, Changhoon , Diana, Anna , Scartozzi, Mario , Prager, Gerald W. , Avallone, Antonio , Schirripa, Marta , Kim, Il Hwan , Oneda, Ester , Verrico, Monica , Couto, Nuno , Chan, Stephen L. , Personeni, Nicola , Garajova, Ingrid , Farinea, Giovanni , Camera, Silvia , Ikeda, Masafumi , Niger, Monica , Tonini, Giuseppe , Kang, Minsu , Bekaii‐Saab, Tanios , Landriscina, Matteo , Djaballah, Selma Ahcene , Masi, Gianluca , Lonardi, Sara

Mayo Clinic

International Journal of Cancer | May 19, 2025 | Volume: 157 | Issue: 6 | Pages: 1246-1259

10.1002/ijc.35481 | PMID 40387725 Get It

AbstractStandard of care first‐line systemic treatment for advanced biliary tract cancer includes chemo‐immunotherapy with gemcitabine, cisplatin, and durvalumab, followed by maintenance durvalumab monotherapy. The present work aims to investigate the differences in baseline clinical and molecular characteristics between patients with early progression during chemo‐immunotherapy and those who reach durvalumab maintenance therapy. The study population included patients with unresectable, locally advanced, or metastatic BTC who received treatment at 38 clinical Institutions in 12 countries from July 2021 to December 2023. The primary objective of the study was to investigate whether baseline clinical and molecular characteristics differed between patients with early progression during chemo‐immunotherapy versus those reaching durvalumab maintenance therapy. Four hundred forty‐eight patients were included in this study. Two hundred twenty‐seven patients (50.7%) received maintenance with durvalumab monotherapy, whereas 221 (49.3%) did not receive maintenance therapy due to PD during first‐line chemo‐immunotherapy before completing 8 cycles. Results show that patients who received maintenance were more likely to be older (≥70 years), have an ECOG = 0, locally advanced disease, and a neutrophil‐to‐lymphocyte ratio (NLR) <3. A higher proportion of patients with BAP1 mutations received maintenance, while TP53 mutations were more common in those who progressed early. According to the present analysis, a substantial proportion of patients (50.7%) with advanced BTC who were treated with chemotherapy plus durvalumab proceeded to receive maintenance therapy with durvalumab monotherapy, with a median treatment duration of 4.4 cycles. Patients ≥70 years, with ECOG PS 0, with locally advanced disease, and with NLR <3 had a higher likelihood of receiving maintenance therapy.
Standardizing the Definition of Each Colon Cancer Segment: Delphi Consensus on Clinical Decision-Making for Oncologic Outcomes
Kuzu, Mehmet Ayhan , Parvaiz, Amjad , Görgün, Emre , Wexner, Steven D. , Dozois, Eric J. , Hohenberger, Werner , Mišković, Danilo , Sugihara, Kenichi , Spinelli, Antonino , Wiggers, Theo , Basany, Eloy Espin, Uriburu, Juan C Patrón , Perez, Rodrigo Oliva , Lynch, Craig, Liu, Zheng , Chowdri, Nisar Ahmad , Madoff, Robert D. , West, Nick P, Şahin, Turgut , Bordeianou, Liliana , Group, On behalf of the Colon Cancer Delphi Consensus Study, Koh, Cherry , Perry, William , Park, Ji Won , Spinelli, Antonino , Wexner, Steven D , Perry, William R , Gaertner, Wolfgang B. , Benlice, Çiğdem , Bertelsen, Claus Anders , Lee, Woo-Yong , Möslein, Gabriela , Владимирович, Царьков Петр , Basany, Eloy Espin, Hahnloser, Dieter , Nilsson, Per Johan , Brown, Gina , Rouanet, Philippe , West, Nick P, Elhan, Atilla Halil , Group, On behalf of the Colon Cancer Delphi Consensus Study

Mayo Clinic

Diseases of the Colon & Rectum | April 11, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1097/dcr.0000000000003739 | PMID 40214091 Get It

BACKGROUND: Data registries lack a definitive classification system that distinguishes different locations of colon cancer from one another. OBJECTIVE: To establish an international consensus on the definition of primary colon cancer segment locations. DESIGN: Between December 2022 and June 2023, Delphi survey study was conducted to seek opinions from relevant international experts and eventually develop a consensus definition of each colon cancer segment. SETTING: Three-round online-based Delphi survey study. INTERVENTIONS: Online survey included 17 questions. In the first two rounds, participating experts were asked to rank each statement on a scale of 1–9 (9 is the most relevant). Consensus statements and definitions were revised according to results, obtaining a consensus score of 7–9. During the third round and online meeting, definitions and statements reached a moderate or high consensus(above 4 in more than 70% of participants) were included. MAIN OUTCOME AND MEASURE: Primary goal of our project was focused on precisely localizing the specific segment affected by primary colon cancer, rather than to identify surgical treatment or type of resection needed for particular segment. RESULTS: The first round included 331 experts, 301 (91%) completed the second round, and 295 (98%) completed the final round. Experts strongly supported the use of a “10 cm rule” to describe colon cancer sites at the flexures and anatomical landmarks for other segments. Regarding the definition of rectosigmoid cancer, experts from America and Europe reached a high consensus that the term rectosigmoid as a colon cancer location must be abolished in contrast to experts from Asia. Description of cancers overlapping segments achieved a consensus of 64%. LIMITATIONS: Subjective decisions are based on individual expert clinical experience. CONCLUSIONS: This Delphi survey, the first internationally conducted consensus study, achieved a remarkable level of consensus among a panel of global experts. Ambiguity still exists regarding overlapping lesions. See Video Abstract .
Definitions, diagnosis, and management of postoperative recurrence in Crohn’s disease patients with permanent ileostomy—a systematic review and meta-analysis
Abushamma, Suha , Yadete, Tesfaye , Nero, Neil , Falloon, Katherine , Parker, Claire E. , Ahuja, Vineet, Armuzzi, Alessandro , Bemelman, Willem A. , Bruining, David H. , Feagan, Brian G. , Hart, Ailsa, Leong, Rupert W. , Narula, Neeraj , Raine, Tim , Singh, Siddharth , Sparrow, Miles , Spinelli, Antonino , Koughnett, Julie Ann Van, Solitano, Virginia , Yuan, Yuhong , Rieder, Florian , Deepak, Parakkal , Dignass, Axel , Fulmer, Clifton , Halfvarson, Jonas , Holubar, Stefan D , Ma, C , Magro, F , McCurdy, Jeffrey D , Narula, Neeraj , Panes, Julian , Raine, Tim , Regueiro, Miguel , Spinelli, Antonino , Rieder, Florian , Solitano, Virginia , Leong, Rupert W , Abreu, María T. , Ahuja, Vineet , Deepak, Parakkal , Dotan, Iris , Fulmer, Clifton G. , Hart, Ailsa , Holubar, Stefan D. , Ma, Christopher , Magro, Fernando , Panés, Julián , Regueiro, Miguel , Rogler, Gerhard , Vuyyuru, Sudheer K. , Jairath, Vipul

Mayo Clinic

Journal of Crohn's and Colitis | March 11, 2025 | Volume: 19 | Issue: 4 | Pages: No page available

10.1093/ecco-jcc/jjaf041 | PMID 40066499 Get It

Abstract Background and Aims Over 10% of patients with Crohn’s disease require permanent ileostomy. We aimed to summarize the existing data on diagnosis, definitions of recurrence, and management of Crohn’s disease patients with permanent ileostomy. Methods MEDLINE, Embase, and CENTRAL databases were searched from inception to February 6, 2024. Randomized controlled trials, cohort and cross-sectional studies, and case series of more than 5 patients reporting on postoperative recurrence or the need for surgery in patients with Crohn’s disease and permanent ileostomy were included. Search results were independently screened, and full text of all titles meeting eligibility criteria was obtained. Outcomes of interest included diagnostic techniques, recurrence definitions, and management approaches. We estimated pooled rates (with 95% confidence interval [CI]) of recurrence. Results Thirty cohort studies including 2055 Crohn’s patients with permanent ileostomy were included (53% female, median age at the time of ileostomy creation 32 years, the most common reason for ileostomy was refractory disease). The postoperative recurrence rate was 27% (95% CI, 21.3–33.3, 26 studies, 451/1805 patients). Modalities for diagnosis of Crohn’s disease recurrence were symptoms (15 studies), endoscopy (4 studies), histology from endoscopic biopsies (2 studies), imaging (5 studies), and surgery (22 studies). The reported definitions of recurrence for each modality were heterogeneous. Conclusions There is a lack of standardized monitoring tools and criteria for diagnosing recurrence in patients with Crohn’s disease and permanent ileostomy. The results of this systematic review will form the basis of a global expert recommendation exercise focused on developing management standards and trial endpoints for this condition.
Colorectal cAncer and CrohN's DIsease study (CANDID): An international multicentre retrospective audit
Garoufalia, Zoe , Dourado, Justin , Boutros, Marylise , Celentano, Valerio , Davies, Justin , Fleshner, Phillip , Gefen, Rachel , Holubar, Stefan D. , El‐Hussuna, Alaa , Keller, Deborah S. , Pellino, Gianluca , Shawki, Sherief , Siakavellas, Spyros I. , Spinelli, Antonino , Warusavitarne, Janindra, Wexner, Steven D. , Spinelli, Antonino , Holubar, Stefan D , Wexner, Steven D , Emile, Sameh Hany , Brady, R , Horesh, Nir , Lightner, Amy L.

Mayo Clinic

Colorectal Disease | January 27, 2025 | Volume: 27 | Issue: 2 | Pages: No page available

10.1111/codi.70005 Get It

AbstractBackgroundInflammatory bowel disease (IBD) affects more than 10 million people worldwide. Men and women are equally affected by Crohn's disease (CD). It has been shown that patients with CD are at an increased risk of a colorectal cancer (CRC) diagnosis and CRC‐related mortality. During the last two decades, biological therapies have revolutionized the treatment of CD. There are no current studies investigating the prevalence of CRC in patients with CD in the era of biological therapy and the possible features of patients with CD who are at high risk of developing CRC.AimWe aim to assess the prevalence of CRC, risk factors and profile of CRC in patients with CD receiving biological treatment compared with those who are not under biological therapy and the impact of CD‐associated colorectal strictures on CRC development. The study hypothesis is that the use of biological therapy in the control of CD activity may decrease the risk of developing CRC.Study design and settingAn international, retrospective, snapshot of the prevalence of CRC in patients with CD, reported according to the SPIRIT guidelines. The study will involve centres that hold regular IBD multidisciplinary team meetings and have both IBD colorectal surgeons and gastroenterologists. Each participating centre will provide a local consultant lead and a local trainee lead. Data will be collected within a 2‐year recruitment period (January 2017–January 2019).Study populationAdult patients who presented with CD during the study period. Patients with an incidental diagnosis of CD during evaluation for CRC will be excluded.Statistical planBaseline patient characteristics will be summarized using the appropriate descriptive statistics. Univariable, multivariable and Cox regression models will be used to identify factors significantly associated with CRC. For noncontinuous variables a comparison between the subgroups will be carried out using the chi‐square test corrected by Fisher's exact test if appropriate. A p‐value of <0.05 will be considered statistically significant.Data storageData will be stored on a secured server, pin‐code protected according to the local data management agreement.
Efficacy of cisplatin-gemcitabine-durvalumab in patients with advanced biliary tract cancer experiencing early vs late disease relapse after surgery: a large real-life worldwide population
Prinzi, Federica Lo , Salani, Francesca , Antonuzzo, Lorenzo , Satake, Tomoyuki, Vandeputte, Hanne, Pressiani, Tiziana , Finkelmeier, Fabian , Pircher, Chiara , Braconi, Chiara , Pastorino, Alessandro , Castet, Florian , Parisi, Alessandro , Perkhofer, Lukas , Adeva, Jorge , Spinelli, Gian Paolo , Rodriquenz, Maria Grazia , Leo, Silvana, Alvim, Cecilia Melo, Roque, Ricardo , Rosa, Antonio De, Lavacchi, Daniele, Dekervel, Jeroen , Balsano, Rita , Viola, Massimo, Silvestro, Lucrezia , Boccaccino, Alessandra , Himmelsbach, Vera, Zanuso, Valentina , Rimassa, Lorenza , Casadei‐Gardini, Andrea , Lo Prinzi, Federica , Abidoye, Oluseyi , Parisi, Alessandro , Ikeda, Masafumi , Antonuzzo, Lorenzo , Casadei-Gardini, Andrea , Finkelmeier, Fabian , Castet, Florian , Adeva, Jorge , Rimassa, Lorenza , Casadei-Gardini, Andrea , Pressiani, Tiziana , Roque, Ricardo , Salani, Francesca , De Rosa, Antonio , Dekervel, Jeroen , Rimini, Margherita , Rizzato, Mario Domenico , Camera, Silvia , Vivaldi, Caterina , Lucchetti, Jessica , Kim, Jin Won , Rapposelli, Ilario Giovanni , Tamberi, Stefano , Giordano, Guido , Chon, Hong Jae , Tamburini, Emiliano , Yoo, Changhoon , Diana, Anna , Scartozzi, Mario , Prager, Gerald W. , Avallone, Antonio , Schirripa, Marta , Kim, Il Hwan , Oneda, Ester , Verrico, Monica , Chan, Stephen L. , Personeni, Nicola , Garajova, Ingrid , Fornaro, Lorenzo , Rossari, Federico , Ikeda, Masafumi , Niger, Monica , Tonini, Giuseppe , Kang, Minsu , Bekaii‐Saab, Tanios , Esposito, Luca , Landriscina, Matteo , Djaballah, Selma Ahcene , Masi, Gianluca , Lonardi, Sara

Mayo Clinic

The Oncologist | September 6, 2024 | Volume: 30 | Issue: 3 | Pages: No page available

10.1093/oncolo/oyae256 | PMID 39427227 Get It

Abstract Background In the TOPAZ-1, patients with biliary tract cancers (BTC) and recurrence within 6 months after surgery were excluded, even if this event is frequently observed in clinical practice. Our study aimed to assess if the efficacy of cisplatin-gemcitabine-durvalumab (CGD) in this population is comparable to that reported in the phase 3 trial. Methods The study cohort included patients with BTC who underwent surgery on the primary tumor, experienced disease recurrence occurring ≤6 months or &gt;6 months after surgery or after the end of adjuvant therapy and started CGD. The primary objectives were overall survival (OS) and progression free survival (PFS). Results A total of 178 patients were enrolled. No significant differences were observed between early and late relapse groups in OS (23.4 months vs not reached; HR 1.26; 95% CI, 0.67-2.37; P = .45) and PFS [7.0 months vs 9.8 months; HR 1.3(95% CI, 0.9-2.1) P = .13]. Overall response rate and disease control rate (P = .33 and P = .62) were comparable between the 2 groups, as the overall safety profile. In addition, we compared survival outcomes between the selected population and a historical cohort of patients with BTC treated with cisplatin-gemcitabine (CG) and found that despite the absence of statistical significance, CGD showed an outcome trend compared with CG regardless of the time of recurrence after surgery or adjuvant chemotherapy [(CG ≤ 6 vs CGD ≤ 6 months: HR 0.59, 95%CI, 0.35-1.01, P = .05; HR 0.70; 95%CI, 0.46-1.06, P = .09, OS and PFS, respectively) and (CG &gt; 6 vs. CGD &gt; 6 months: HR 0.50; 95%CI, 0.29-0.88, P = 0.0165; HR 0.54; 95%CI, 0.35-0.84, P = .0068, OS and PFS, respectively)]. Conclusion Our analysis suggests that CGD retains its efficacy independently of the timing of relapse after surgery or completion of adjuvant treatment in patients with advanced BTC.
Stepwise Functional Brain Architecture Correlates with Atrophy in Progressive Supranuclear Palsy
Spinelli, Edoardo Gioele , Bottale, Ilaria, Basaia, Silvia , Volonté, Maria Antonietta , Prioni, Sara , Villa, Cristina , Josephs, Keith A. , Whitwell, Jennifer L. , Agosta, Federica , Basaia, Silvia , Filippi, Massimo , Agosta, Federica , Ghirelli, Alma , Canu, Elisa , Castelnovo, Veronica , Galantucci, Sebastiano , Magnani, Giuseppe , Caso, Francesca , Cecchetti, Giordano , Caroppo, Paola , Filippi, Massimo

Mayo Clinic

Movement Disorders | June 17, 2024 | Volume: 39 | Issue: 9 | Pages: 1493-1503

10.1002/mds.29887 | PMID 38881298 Get It

Abstract Background Stepwise functional connectivity (SFC) detects whole‐brain functional couplings of a selected region of interest at increasing link‐step topological distances. Objective This study applied SFC to test the hypothesis that stepwise architecture propagating from the disease epicenter would shape patterns of brain atrophy in patients with progressive supranuclear palsy–Richardson's syndrome (PSP‐RS). Methods Thirty‐six patients with PSP‐RS and 44 age‐matched healthy control subjects underwent brain magnetic resonance imaging on a 3‐T scanner. The disease epicenter was defined as the peak of atrophy observed in an independent cohort of 13 cases with postmortem confirmation of PSP pathology and used as seed region for SFC analysis. First, we explored SFC rearrangements in patients with PSP‐RS, as compared with age‐matched control subjects. Subsequently, we tested SFC architecture propagating from the disease epicenter as a determinant of brain atrophy distribution. Results The disease epicenter was identified in the left midbrain tegmental region. Compared with age‐matched control subjects, patients with PSP‐RS showed progressively widespread decreased SFC of the midbrain with striatal and cerebellar regions through direct connections and sensorimotor cortical regions through indirect connections. A correlation was found between average link‐step distance from the left midbrain in healthy subjects and brain volumes in patients with PSP‐RS ( r = 0.38, P < 0.001). Conclusions This study provides comprehensive insights into the topology of functional network rearrangements in PSP‐RS and demonstrates that the brain architectural topology, as described by SFC propagating from the disease epicenter, shapes the pattern of atrophic changes in PSP‐RS. Our findings support the view of a network‐based pathology propagation in this primary tauopathy. © 2024 The Author(s). Movement Disorders published by Wiley Periodicals LLC on behalf of International Parkinson and Movement Disorder Society.
Short‐term outcomes of surgical treatment for primary ileocaecal Crohn's disease: Results of the Crohn's(urg) study, a multicentre, retrospective, comparative analysis between inflammatory and complicated phenotypes
Avellaneda, Nicolás , Pellino, Gianluca , Maroli, Annalisa , Bislenghi, Gabriele , Colpaert, Jan , D’Hoore, André , Giorgi, Lorenzo , Juachon, Patrizia, Harsløf, Sanne , Overstraeten, Anthony de Buck van , Merchea, Amit , Shaker, Andrew, Maruyama, Beatriz Yuki , Wexner, Steven D. , Garoufalia, Zoe , Chen, Zhihui , Rrupa, Djana , Haanappel, Anouck , Potolicchio, Analia, Spinelli, Antonino , Bislenghi, Gabriele , Colpaert, Jan , Harsløf, Sanne , Holubar, Stefan D , Merchea, Amit , Wexner, Steven D , Spinelli, Antonino , Tottrup, Anders, Carvello, Michele , Olivera, Pablo Andres , Gomez, Javier, Holubar, Stefan D. , Lincango-Naranjo, Eddy , Steele, Scott R. , Martí, Marc , Kraft, Miquel , Kotze, Paulo Gustavo , Chen, Zhihui, Hahnloser, Dieter , Buskens, Christianne Johanna , Warusavitarne, Janindra H. , Williams, Katherine J., Christensen, Peter , Wolthuis, Albert M.

Mayo Clinic

Colorectal Disease | June 10, 2024 | Volume: 26 | Issue: 7 | Pages: 1415-1427

10.1111/codi.17056 | PMID 38858815 Get It

Abstract Aim Recent evidence challenges the current standard of offering surgery to patients with ileocaecal Crohn's disease (CD) only when they present complications of the disease. The aim of this study was to compare short‐term results of patients who underwent primary ileocaecal resection for either inflammatory (luminal disease, earlier in the disease course) or complicated phenotypes, hypothesizing that the latter would be associated with worse postoperative outcomes. Method A retrospective, multicentre comparative analysis was performed including patients operated on for primary ileocaecal CD at 12 referral centres. Patients were divided into two groups according to indication of surgery for inflammatory (ICD) or complicated (CCD) phenotype. Short‐term results were compared. Results A total of 2013 patients were included, with 291 (14.5%) in the ICD group. No differences were found between the groups in time from diagnosis to surgery. CCD patients had higher rates of low body mass index, anaemia (40.9% vs. 27%, p < 0.001) and low albumin (11.3% vs. 2.6%, p < 0.001). CCD patients had longer operations, lower rates of laparoscopic approach (84.3% vs. 93.1%, p = 0.001) and higher conversion rates (9.3% vs. 1.9%, p < 0.001). CCD patients had a longer hospital stay and higher postoperative complication rates (26.1% vs. 21.3%, p = 0.083). Anastomotic leakage and reoperations were also more frequent in this group. More patients in the CCD group required an extended bowel resection (14.1% vs. 8.3%, p : 0.017). In multivariate analysis, CCD was associated with prolonged surgery (OR 3.44, p = 0.001) and the requirement for multiple intraoperative procedures (OR 8.39, p = 0.030). Conclusion Indication for surgery in patients who present with an inflammatory phenotype of CD was associated with better outcomes compared with patients operated on for complications of the disease. There was no difference between groups in time from diagnosis to surgery.
P433 Short-term outcomes of surgical treatment in primary ileocecal Crohn’s disease patients. Results of Crohn’s(urg) study, multicenter, retrospective, comparative analysis between indications for luminal and complicated phenotype
Bislenghi, Gabriele , D’Hoore, André , Juachon, Patrizia, Harsløf, Sanne , Gomez, Joanne Michelle D. , Merchea, Amit , Shacker, A, Gallostra, M Marti, Maruyana, B Yuki, Garoufalia, Zoe , Zhihui, C, Rrupa, Djana , Haanappel, Anouck , Giorgi, Lorenzo , Avellaneda, Nicolás , Pellino, Gianluca , Maroli, Annalisa , Tottrup, A, Colpaert, J, Giorgi, L, Overstraeten, Anthony de Buck van , Olivera, Pablo Andres , Gomez, J, Holubar, Stefan D. , Lincango-Naranjo, Eddy , Steele, Scott R. , Gallostra, M Marti, Kraft, Miquel , Kotze, Paulo Gustavo , Wexner, Steven D. , Zhihui, C, Hahnloser, Dieter , Buskens, Christianne Johanna , Warusavitarne, Janindra H. , Williams, K, Christensen, Peter , Spinelli, Antonino

Mayo Clinic

Journal of Crohn's and Colitis | January 24, 2024 | Volume: 18 | Issue: Supplement_1 | Pages: i881-i883

10.1093/ecco-jcc/jjad212.0563 Get It

Abstract Background Recent evidence challenges the current standard of offering surgery to patients with ileocecal Crohn’s disease only when they present complications of the disease. Methods A retrospective, multicenter comparative analysis was performed including patients operated for primary ileocecal CD at 12 referral centers. Patients were divided in 2 groups, according to indication of surgery for inflammatory (ICD) or complicated (CCD) phenotype. Short-term results were compared. Patients operated on for primary isolated ileocaecal CD (last 50 cm of the terminal ileum and cecum), either for predominantly inflammatory phenotype or for complications of the disease (stricturing or fistulizing pattern), between January 2012 - December 2021 were considered eligible to participate in this study. Patients with previous abdominal procedures for CD, and patients who had activity of the disease in other intestinal segments other than the ileocaecal region at the time of surgery, were excluded from the study. Results 2013 patients were included, 291 (14.5%) in the ICD group. No differences were found between groups in time from diagnosis to surgery or in the levels of exposure to biologic drugs before indication of surgery. CCD patients had higher rates of low BMI, anemia (40.9 vs. 27%, p: &lt; 0.001), and low albumin (11.3 vs. 2.6%, p: &lt; 0.001). CCD patients had longer operations, lower rates of laparoscopic approach (84.3 vs. 93.1%, p: 0.001), and higher conversion rates (9.3 vs. 1.9%, p: &lt; 0.001). CCD had longer hospital stay and higher postoperative complication rates (26.1 vs. 21.3%, p: 0.083). Anastomotic leakage and reoperations were also more frequent in this group. More patients in the CCD group required an extended bowel resection (14.1 vs. 8.3%, p: 0.017). In multivariate analysis, CCD was associated with prolonged surgeries (OR: 3.44, p: 0.001) and requirements of multiple intraoperative procedures (OR: 8.39, p: 0.030). Conclusion Indication of surgery in patients who present an inflammatory phenotype of CD was associated with better outcomes when compared to patients operated on for complications of the disease, without a difference between groups in time from diagnosis to surgery.